Enterolactone

Last updated
Enterolactone
Enterolactone.png
Names
Preferred IUPAC name
(3R,4R)-3,4-Bis[(4-hydroxyphenyl)methyl]oxolan-2-one
Other names
(−)-Enterolactone
Identifiers
3D model (JSmol)
AbbreviationsENL
ChEMBL
ChemSpider
ECHA InfoCard 100.162.708 OOjs UI icon edit-ltr-progressive.svg
EC Number
  • 634-756-3
KEGG
PubChem CID
UNII
  • InChI=1S/C18H18O4/c19-15-5-1-3-12(8-15)7-14-11-22-18(21)17(14)10-13-4-2-6-16(20)9-13/h1-6,8-9,14,17,19-20H,7,10-11H2/t14-,17+/m0/s1
    Key: HVDGDHBAMCBBLR-WMLDXEAASA-N
  • C1[C@@H]([C@H](C(=O)O1)CC2=CC(=CC=C2)O)CC3=CC(=CC=C3)O
Properties
C18H18O4
Molar mass 298.338 g·mol−1
Hazards
GHS labelling:
GHS-pictogram-exclam.svg
Warning
H315, H319, H335
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, P501
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Yes check.svgY  verify  (what is  Yes check.svgYX mark.svgN ?)

Enterolactone is an organic compound classified as an enterolignan. It is formed by the action of intestinal bacteria on plant lignan precursors present in the diet.

Contents

Sources

Many dietary plant lignan precursors, such as secoisolariciresinol, matairesinol, lariciresinol, pinoresinol, and sesamin, can be metabolized by gut microbes to enterolactone. [1] [2] [3] In edible plants lignans are bound to the fiber fraction and therefore fiber-rich food products, such as cereals, vegetables, fruits and berries, are generally good sources of lignans and enterolactone. The richest known dietary sources of enterolactone precursors are flaxseed and sesame seed. [4] [5] [6] Since enterolactone is produced by specific species of gut microbiota, the capacity to produce it varies between people. [7] Antibiotic treatments can abolish the capacity to produce enterolactone. It may take up to a year before enterolactone production is restored. [8] [9]

Health effects

Enterolactone is suggested to possess beneficial health effects in humans. In epidemiological studies lower concentrations of enterolactone have been observed in breast cancer patients compared to healthy controls, which may suggest that enterolactone is anti-carcinogenic. Enterolactone and lignans may also be protective against cardiovascular disease. [10] [11]

References

  1. Lampe JW (2003). "Isoflavonoid and lignan phytoestrogens as dietary biomarkers". J Nutr. 133 (Suppl 3): 956S –964S. doi: 10.1093/jn/133.3.956S . PMID   12612182.
  2. Peñalvo JL, Heinonen SM, Aura AM, Adlercreutz H (May 2005). "Dietary sesamin is converted to enterolactone in humans". J. Nutr. 135 (5): 1056–1062. doi: 10.1093/jn/135.5.1056 . PMID   15867281.
  3. Heinonen, S; Nurmi, T; Liukkonen, K; Poutanen, K; Wähälä, K; Deyama, T; Nishibe, S; Adlercreutz, H (2001). "In vitro metabolism of plant lignans: New precursors of mammalian lignans enterolactone and enterodiol". Journal of Agricultural and Food Chemistry. 49 (7): 3178–86. doi:10.1021/jf010038a. PMID   11453749.
  4. Milder, I. E.; Arts, I. C.; Van De Putte, B; Venema, D. P.; Hollman, P. C. (2005). "Lignan contents of Dutch plant foods: A database including lariciresinol, pinoresinol, secoisolariciresinol and matairesinol". The British Journal of Nutrition. 93 (3): 393–402. doi: 10.1079/bjn20051371 . PMID   15877880.
  5. Thompson, L. U.; Boucher, B. A.; Liu, Z; Cotterchio, M; Kreiger, N (2006). "Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestan". Nutrition and Cancer. 54 (2): 184–201. doi:10.1207/s15327914nc5402_5. PMID   16898863. S2CID   60328.
  6. Smeds, A. I.; Eklund, P. C.; Sjöholm, R. E.; Willför, S. M.; Nishibe, S; Deyama, T; Holmbom, B. R. (2007). "Quantification of a broad spectrum of lignans in cereals, oilseeds, and nuts". Journal of Agricultural and Food Chemistry. 55 (4): 1337–46. doi:10.1021/jf0629134. PMID   17261017.
  7. Clavel, T; Doré, J; Blaut, M (2006). "Bioavailability of lignans in human subjects". Nutrition Research Reviews. 19 (2): 187–96. doi: 10.1017/S0954422407249704 . PMID   19079885.
  8. Setchell, K. D.; Lawson, A. M.; Borriello, S. P.; Harkness, R; Gordon, H; Morgan, D. M.; Kirk, D. N.; Adlercreatz, H; Anderson, L. C.; Axelson, M (1981). "Lignan formation in man--microbial involvement and possible roles in relation to cancer". Lancet. 2 (8236): 4–7. doi:10.1016/s0140-6736(81)90250-6. PMID   6113409. S2CID   39049097.
  9. Kilkkinen, A; Pietinen, P; Klaukka, T; Virtamo, J; Korhonen, P; Adlercreutz, H (2002). "Use of oral antimicrobials decreases serum enterolactone concentration". American Journal of Epidemiology. 155 (5): 472–7. doi: 10.1093/aje/155.5.472 . PMID   11867359.
  10. Adlercreutz, H (2007). "Lignans and human health". Critical Reviews in Clinical Laboratory Sciences. 44 (5–6): 483–525. doi:10.1080/10408360701612942. PMID   17943494. S2CID   31753060.
  11. Peterson, J; Dwyer, J; Adlercreutz, H; Scalbert, A; Jacques, P; McCullough, M. L. (2010). "Dietary lignans: Physiology and potential for cardiovascular disease risk reduction". Nutrition Reviews. 68 (10): 571–603. doi:10.1111/j.1753-4887.2010.00319.x. PMC   2951311 . PMID   20883417.